logo

For the Inventor, By the Inventor

Sundbyberg, Sweden

Biolamina Ab


USPTO Granted Patents = 22



Trademarks = 6

Forward Citations = 21

Loading Chart...
Loading Chart...

21 inventors (with patents filed for the assignee):

goldMedal Karl Kristian Tryggvason (14 out of 30 patents)

silverMedal Sergey Rodin (6 out of 7 patents)

bronzeMedal Anna Domogatskaya (5 out of 6 patents)

4.  Kristian Tryggvason (5 out of 5 patents)

5.  Outi Hovatta (4 out of 4 patents)

6.  Karl Tryggvason (4 out of 5 patents)

7.  Yan Wen Yap (3 out of 3 patents)

8.  Agnete Kirkeby (2 out of 2 patents)

9.  Malin Pernilla Parmar (2 out of 2 patents)

10.  Sun Yi (2 out of 2 patents)

11.  Louise Kristina Hagbard (2 out of 2 patents)

12.  Carl Gunnar Jesper Ericsson (2 out of 2 patents)

13.  Katherine Rachel Cameron (2 out of 2 patents)

14.  David Colin Hay (2 out of 3 patents)

15.  Stuart John Forbes (2 out of 2 patents)


22 patents:

1. 12680078 - Differentiation of pluripotent stem cells and cardiac progenitor cells into striated cardiomyocyte fibers using laminins LN-511, LN-521 and LN-221 (2026-07-14),
2. 12516287 - Methods for producing retinal pigment epithelium cells (2026-01-06),
3. 12391915 - Maintenance of differentiated cells with laminins (2025-08-19),
4. 12378527 - Differentiation of pluripotent stem cells using laminins LN-511, LN-521 and LN-221 (2025-08-05),
5. 12195757 - Methods of producing RPE cells (2025-01-14),
6. 11767509 - Methods of producing RPE cells (2023-09-26),
7. 11713448 - Methods for producing hepatocytes (2023-08-01),
8. 11236302 - Methods and compositions for producing stem cell derived dopaminergic cells for use in treatment of neurodegenerative diseases (2022-02-01),
9. 11155781 - Maintenance of differentiated cells with laminins (2021-10-26),
10. 11001807 - Differentiation of pluripotent stem cells and cardiac progenitor cells into striated cardiomyocyte fibers using laminins LN-511, LN-521 and LN-221 (2021-05-11),
11. 10889801 - Methods of producing RPE cells (2021-01-12),
12. 10829733 - Composition and method for enabling proliferation of pluripotent human stem cells (2020-11-10),
13. 10683486 - Methods for producing hepatocytes (2020-06-16),
14. 10344259 - Methods and compositions for producing stem cell derived dopaminergic cells for use in treatment of neurodegenerative diseases (2019-07-09),
15. 10240124 - Cell culture substrate comprising a laminin and a cadherin (2019-03-26),
Biolamina AB is a biotechnology company based in Sundbyberg, Sweden, specializing in the development and manufacturing of high-quality extracellular matrix products. These products are designed to support cell culture and tissue engineering applications, facilitating advancements in regenerative medicine and cell therapy. The company focuses on providing innovative solutions that enhance cell growth and functionality, contributing to research and development in the life sciences sector. Biolamina's expertise lies in creating biomaterials that mimic natural environments for cells.
Profile summary based on public USPTO records.

logo

Company Badge

USPTO Data Jan 1 1976 - Sep 29 2026

22 Patents

#2 in Sundbyberg

#298 in Sweden

#28,724 in the World

Sundbyberg, SE
Sundbyberg, Sweden

Biolamina Ab

Forward Citations = 21

21 inventors:

goldMedal Karl Kristian Tryggvason (14 out of 30 patents)

silverMedal Sergey Rodin (6 out of 7 patents)

bronzeMedal Anna Domogatskaya (5 out of 6 patents)

4.  Kristian Tryggvason (5 out of 5 patents)

5.  Outi Hovatta (4 out of 4 patents)

Please report any incorrect information to [email protected]
Loading…